Neil Woodford, manager of Invesco Perpetual's £20bn Income funds, believes AstraZeneca is finally turning a corner after a difficult 2012.
Pascal Soriot, formerly COO at Roche AG, took over as CEO at AstraZeneca last October and has been tasked with returning the company's fortunes around. Having suspended share buybacks and warned of a difficult year ahead, Soriot's arrival has underwhelmed some investors. But Woodford (pictured) said he expects the firm to return to growth, triggering a long-awaited re-rating of AstraZeneca shares over the longer-term. "Only three months in and [Soriot] has already made some significant changes to the senior management team and has a clear view on what the business needs to do to re...
To continue reading this article...
Join Investment Week for free
Signup and gain exclusive members-only insights - all free of charge!
- Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
- Get ahead of regulatory and technological changes affecting fund management
- Important and breaking news stories selected by the editors delivered straight to your inbox each day
- Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
- Be the first to hear about our extensive events schedule and awards programmes
